What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2020-11-24 compared with 2019-11-27 · 619 added, 668 removed, 22 unchanged (98% of the section changed)

DESCRIPTION OF BUSINESS

Research and Development

We are a pharmaceutical company currently engaged

in the research and development of innovative pharmaceutical solutions, including an oral insulin capsule to be used for the treatment

of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides.

Clinical Research Organizations, or CROs, to conduct our clinical studies.

Oral insulin :

We are seeking to

transform the treatment of diabetes through our proprietary flagship product, an orally ingestible insulin capsule, or ORMD-0801.

Our technology allows insulin to travel from the gastrointestinal tract via the portal vein to the bloodstream, revolutionizing

the manner in which insulin is delivered.

It enables the passage in a more physiological manner than current delivery methods of

Our technology is a platform that has the potential to deliver medications and vaccines orally that today can only be

delivered via injection.

FDA Guidance:

In August 2017, during

a call with the U.S.

Food and Drug Administration, or FDA, we were advised that the regulatory pathway for the submission of ORMD-0801

would be a Biologics License Application, or BLA.

If approved the BLA pathway would grant us 12 years of marketing exclusivity

for ORMD-0801, from the approval date, and an additional six months of exclusivity may be granted to us if the product also receives

approval for use in pediatric patients.

The FDA confirmed that the approach to nonclinical toxicology, chemistry manufacturing

controls and qualification of excipients would be driven by their published guidance documents.

and Development

are a pharmaceutical company currently engaged in the research and development of innovative pharmaceutical solutions, including

an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or

pills for delivery of other polypeptides.

We utilize Clinical Research Organizations, or CROs, to conduct our clinical studies.

our research and development efforts, we have successfully developed an oral dosage form intended to withstand the harsh environment

of the stomach and intestines and effectively deliver active insulin or other proteins, such as Glucagon-like peptide-1, or GLP-1,

leptin, and others.

The excipients in the formulation are not intended to modify the proteins chemically or biologically, and

the dosage form is designed to be safe to ingest.

We plan to continue to conduct clinical trials to show the effectiveness of

our technology.

Our proprietary flagship product, an orally ingestible insulin capsule, or ORMD-0801, allows insulin to travel

from the gastrointestinal tract via the portal vein to the bloodstream, revolutionizing the manner in which insulin is delivered.

It enables the passage in a more physiological manner than current delivery methods of insulin.

In August 2017, the U.S.

Food and Drug Administration, or FDA, instructed us that the regulatory pathway for the

submission of ORMD-0801 would be a Biologics License Application, or BLA.

If approved the BLA pathway would grant us 12 years

of marketing exclusivity for ORMD-0801, from the approval date, and an additional six months of exclusivity may be granted to

us if the product also receives approval for use in pediatric patients.

Phase IIb Study:

In May 2018, we initiated

a three-month dose-ranging Phase IIb clinical trial of ORMD-0801.

This placebo controlled, randomized, 90-day treatment clinical

trial was conducted on 269 type 2 diabetic patients in multiple centers throughout the United States pursuant to an Investigational

New Drug application, or IND, with the FDA.

The primary endpoints of the trial were to assess the safety and evaluate the effect

of ORMD-0801 on HbA1c levels over a 90-day treatment period.

Secondary endpoints of the trial included measurements of fasting

plasma glucose, or FPG, post-prandial glucose, or PPG levels, during a mixed-meal tolerance test, or MMTT, and weight.

we began an extension of this protocol for approximately 75 type 2 diabetic patients, who were dosed using a lower dosage.

In November 2019, we announced positive

results from the initial cohort of the Phase IIb trial.

Patients randomized in the trial to once-daily ORMD-0801 achieved a reduction

in mean HbA1c of 0.60% from baseline, or a reduction of 0.54% adjusted for placebo (p value = 0.036).

This 0.54% reduction in HbA1c

is considered clinically meaningful, reflecting an improved glucose control that would result in reduced risk of developing diabetes-related

complications.

Treatment with ORMD-0801 demonstrated an excellent safety profile, with no serious drug-related adverse events and

with no increased frequency of hypoglycemic episodes.

In May 2018, we initiated a three-month dose-ranging Phase IIb clinical trial of ORMD-0801 (Cohort A).

This placebo controlled,

randomized, 90-day treatment clinical trial was conducted on 269 type 2 diabetic patients in multiple centers throughout the United

States pursuant to an Investigational New Drug application, or IND, with the FDA.

The primary endpoints of the trial were to assess

the safety and evaluate the effect of ORMD-0801 on HbA1c levels over a 90-day treatment period.

Secondary endpoints of the trial

included measurements of fasting plasma glucose, or FPG, post-prandial glucose, or PPG levels, during a mixed-meal tolerance test,

or MMTT, and weight.

In May 2019, we initiated an extension of this protocol for approximately 75 type 2 diabetic patients, who

were dosed using a lower dosage of insulin (Cohort B).

In November 2019, we announced positive results from the initial cohort of the Phase IIb trial.

Patients randomized in the

trial to once-daily ORMD-0801 achieved a statistically significant (p-value 0.036) reduction from baseline in HbA1c of 0.60% (0.54%

with placebo adjustment).

This 0.54% reduction in HbA1c is clinically meaningful.

Treatment with ORMD-0801 demonstrated an excellent

safety profile, with no serious drug-related adverse events and with no increased frequency of hypoglycemic episodes when compared

In addition, during this 90-day trial, no weight gain was observed.

initial cohort, 269 U.S.-based patients were enrolled and treated with a dose-increasing approach:

16 mg initial dose, titrated

to 24 mg per dose, and then titrated to 32 mg per dose.

In the initial cohort, 269 U.S.-based patients

were enrolled and treated with a dose-increasing approach:

16 mg initial dose, titrated to 24 mg per dose, and then titrated to

32 mg per dose.

Patients were randomized into three groups to assess dosing frequency:

once-daily (32 mg per day), twice-daily (64 mg per day), thrice daily (96 mg per day).

There was a corresponding placebo for each

treatment arm.

Two hundred nine (209) patients completed treatment to the 12-week endpoint and were included in the data analysis

(24 subjects did not complete the full 12 weeks of treatment).

In addition, due to evidence of treatment-by-center interaction,

two sites (36 patients (13.4% of enrolled subjects)) were excluded from the statistical analysis as they showed results opposite

from the rest of the statistically significant results.

We are still investigating the cause of this discrepancy.

The once-daily

and twice-daily arms achieved statistically significant (p-value 0.036 and 0.042, respectively) reductions from baseline in A1C

of 0.60% (0.54% with placebo adjustment) and 0.59% (0.53% with placebo adjustment), respectively.

The thrice-daily arm did not

meet statistical significance (p-value 0.093).

ORMD-0801 demonstrated an excellent safety profile with no serious drug-related

adverse events.

As our Phase IIb three-month dose-ranging clinical

trial successfully met its primary endpoints, we anticipate initiating two six-month Phase III clinical trials on both type 1 and

type 2 diabetic patients, following which we expect to file a BLA with potential FDA approval by the end of calendar year 2024.

In June 2018, we initiated

a glucose clamp study which will quantify insulin absorption in type 1 diabetic patients treated with ORMD-0801.

The glucose clamp

is a method for quantifying insulin absorption in order to measure a patient’s insulin sensitivity and how well a patient

metabolizes glucose.

This exploratory, randomized, double-blind glucose clamp study is evaluating exposure-response profiles of

type 1 diabetic patients treated with ORMD-0801.

Six patients with HbA1c levels of 10% or below, aged 18-50, are enrolled in the

We expect to receive the results of this study in the first quarter of calendar year

Food Effect Study:

In June 2018, we also

initiated a food effect trial in the United States for ORMD-0801.

This single-blind, five period, randomized, placebo-controlled

crossover trial is evaluating the pharmacokinetics, or PK, and pharmacodynamics of ORMD-0801 taken at different times in relation

to meals in healthy volunteers and patients with type 1 diabetes.

Forty-eight (48) patients are enrolled, including 24 healthy

volunteers and 24 patients with type 1 diabetes.

We expect to receive the results of this

study in the first quarter of calendar year 2020.

In October 2018, we initiated

an exploratory clinical study of ORMD-0801 in patients with nonalcoholic steatohepatitis, or NASH.

The three-month treatment study,

which was approved by Israel’s Ministry of Health, will assess the effectiveness of ORMD-0801 in reducing liver fat content,

inflammation and fibrosis in 30 patients with NASH.

As requested by Israel’s Ministry of Health, the first part of the study

will be conducted on 10 participants and is expected to be completed during first quarter of calendar year 2020.

Toxicology Study (6 Months):

2019, we completed a six-month dosing toxicology study of ORMD-0801, which was initiated in September 2018 following the FDA’s

We expect to receive the results of this study in the first quarter of calendar

Type 1 Study:

In November 2019 we initiated

a crossover study of type 1 diabetic patients to compare the effects of ORMD-0801 given once daily versus the effects of ORMD-0801

given three times daily.

The study is anticipated to include 26 subjects and is expected to be completed in the second quarter

of calendar year 2020.

Oral Glucagon-Like Peptide-1 :

Glucagon-Like Peptide-1, or GLP-1, is an incretin hormone, which is a type of gastrointestinal hormone that stimulates the secretion

of insulin from the pancreas.

The incretin concept was hypothesized when it was noted that glucose ingested by mouth (oral) stimulated

two to three times more insulin release than the same amount of glucose administered intravenously.

In addition to stimulating

insulin release, GLP-1 was found to suppress glucagon release (a hormone involved in the regulation of glucose) from the pancreas,

slow gastric emptying to reduce the rate of absorption of nutrients into the blood stream and increase satiety.

Other important

beneficial attributes of GLP-1 are its effects of increasing the number of beta cells (cells that manufacture and release insulin)

in the pancreas and, possibly, protection of the heart.

In addition to our flagship product, the ORMD-0801 insulin capsule, we

are using our technology for an orally ingestible GLP-1 capsule, or ORMD-0901.

In February 2019, we completed a

Phase I PK trial to evaluate the safety and the pharmacokinetics of ORMD-0901 compared to placebo.

We expect to receive the results

of this study in the first quarter of calendar year 2020.

This study was conducted pursuant to an IND, which we expect to be

followed by a Phase II trial on type 2 diabetic patients which will likely be conducted in the United States under an IND.

once-daily (32 mg per day), twice-daily

(64 mg per day), thrice daily (96 mg per day).

There was a corresponding placebo for each treatment arm.

Two hundred nine (209)

patients completed treatment to the 12-week endpoint and were included in the data analysis (24 subjects did not complete the full

12 weeks of treatment).

The twice-daily arms achieved statistically significant (p-value 0.042) reductions from baseline in HbA1c

of 0.59% (0.53% with placebo adjustment).

The thrice-daily arm did not meet statistical significance (p-value 0.093).

due to evidence of treatment-by-center interaction, two sites (36 patients (13.4% of enrolled subjects)) were excluded from the

statistical analysis as they showed results opposite from the rest of the statistically significant results.

Our internal investigation

as well as an independent investigation did not find a cause for such discrepancy.

In February 2020, we announced positive topline data from the second and final cohort of the Phase IIb trial with a different

regimen across three daily dose ranges (8 mg, 16 mg, 32 mg).

Patients randomized in the trial treated with 8 mg of ORMD-0801 once-daily

achieved a statistically significant (p-value 0.028) observed mean reduction of 1.29% from baseline and a least square mean reduction

of 0.95% from baseline, or 0.81% adjusted for placebo.

Patients who had HbA1c readings above 9% at baseline and received 8 mg

of oral insulin once-daily experienced a 1.26% reduction in HbA1c by week 12.

Treatment with ORMD-0801 at all doses demonstrated

an excellent safety profile, with no serious drug-related adverse events and with no increased frequency of hypoglycemic episodes

or weight gain compared to placebo.

The primary efficacy endpoint was a reduction in HbA1c at week 12.

Phase III Study :

Based on guidance received from the FDA as part of the end-of-phase II meeting process for our oral insulin candidate, ORMD-0801,

we have submitted to the FDA the protocols for our upcoming pivotal Phase III studies.

In line with the FDA’s expectations

and recommendations, we intend to conduct two Phase III studies concurrently in patients with type 2 diabetes.

These studies involve

about 1,125 patients to provide evidence of ORMD-0801’s safety and efficacy in type 2 diabetic patients over a treatment

period of 6 to 12 months.

A geographically diverse patient population will be recruited from multiple sites throughout the United

States, European, and Israel.

Our phase III study will be composed from 2 protocols:

ORA-D-013-1 :

This study will treat type 2 diabetic patients with inadequate glycaemic control who are currently on 1, 2 or 3 oral glucose-lowering

study will recruit 675 patients from 75 clinical sites located throughout the U.S.

Patients will be randomized

1:1:1 in this double-dummy study into cohorts of:

8 mg ORMD-0801 once-daily at night and placebo 45 minutes before breakfast;

mg ORMD-0801 twice-daily, at night and 45 minutes before breakfast;

and placebo twice-daily, at night and 45 minutes before breakfast.

The primary endpoint of the study is to evaluate the efficacy of ORMD-0801 compared to placebo in improving glycaemic control as

assessed by HbA1c, with a secondary efficacy endpoint of assessing the change from baseline in fasting plasma glucose at 26 weeks.

We expect to initiate this trial on the fourth quarter of 2020.

ORA-D-013-2 :

This study will include type 2 diabetic patients with inadequate glycaemic control who are managing their condition with either

diet alone or with diet and metformin monotherapy.

A total of 450 patients will be recruited through 36 sites in the U.S.

sites in Western Europe and Israel.

Patients will be randomized 1:1 into two cohorts dosed with:

8 mg ORMD-0801 at night;

The primary endpoint is to evaluate the efficacy of ORMD-0801 compared to placebo in improving glycaemic control as assessed

by HbA1c over a 26-week treatment period, with a secondary efficacy endpoint of assessing the change from baseline in fasting plasma

glucose at 26 weeks.

We expect to initiate this trial on the first half of 2021.

If we successfully

complete the pivotal studies, we expect to conduct a pre-BLA meeting with the FDA to finalize the plans and data for the BLA submission.

After BLA submission and review, if the BLA is approved by the FDA, a full 12 years of marketing exclusivity would be granted.

June 2020, we presented preliminary data from our open-label study of the first 8 patients of a planned 40-patient multi-center

(U.S., Europe and Israel) pilot study, aimed to assess the safety, tolerability, and early effects of 16 mg ORMD-0801 (2x8 mg capsules)

on liver fat in type 2 diabetic patients with nonalcoholic steatohepatitis, or NASH.

The 12-week, once-daily treatment had no serious

adverse events, and induced an observed mean 6.9±6.8% reduction in liver fat content (p value:

0.035), and the relative

reduction was 30%, as measured by MRI-derived proton density fat fraction.

In parallel, concentrations of gamma-glutamyltransferase

(GGT), a key marker of chronic hepatitis, were significantly lower after 12 weeks of treatment as compared to baseline (-14.6±13.1

In November 2019, we initiated a crossover study of type 1 diabetic patients to compare the effects of ORMD-0801

given once daily versus the effects of ORMD-0801 given three times daily.

This study showed no statistically significant, or clinically

meaningful differences in total exogenous insulin requirements, or plasma glucose levels in type 1 diabetic subjects treated with

ORMD-0801 8mg dosed once daily in the evening compared to those dosed with ORMD-0801 three times daily.

GLP-1 is an incretin hormone, which stimulates the secretion of insulin from the pancreas.

In addition to our flagship

product, the ORMD-0801 insulin capsule, we are using our technology for an orally ingestible GLP-1 capsule, or ORMD-0901.

In February 2019, we

completed a Phase I pharmacokinetic trial to evaluate the safety and pharmacokinetics of ORMD-0901 compared to placebo.

this trial results, we will conduct a follow-up Phase I trial in type 2 diabetic patients which will start its enrollment by the

end of 2020 in the United States under an IND submitted to the FDA.

following table gives an overview of the above described primary R&D pipeline:

clinical trials are planned in order to substantiate our results as well as for purposes of making future filings for drug approval.

We also plan to conduct further research and development by deploying our proprietary drug delivery technology for the delivery

of other polypeptides in addition to insulin, and to develop other innovative pharmaceutical products.

Other Products:

We are developing a new drug candidate, a weight loss treatment in the form of an oral leptin capsule.

We anticipate initiating

a proof of concept single dose study for this candidate to evaluate its pharmacokinetics and pharmacodynamics (glucagon reduction)

in 10 type 1 adult diabetic patients.

During the third quarter of 2020, we finalized the study without any safety issues, and we

are waiting for the final lab results.

oral insulin capsule is currently manufactured by Fidelio Healthcare, a diversified European Contract Development and Manufacturing

Organization (CDMO) in the pharmaceutical and healthcare industries.

July 2010, Oramed Ltd.

entered into the Manufacturing and Supply Agreement, or MSA, with Sanofi-Aventis Deutschland GMBH, or Sanofi-Aventis.

According to the MSA, Sanofi-Aventis will supply Oramed Ltd.

with specified quantities of recombinant human insulin to be used

for clinical trials.

We also entered into an Insulin Supply Agreement in September 2020 with Hefei Tianmai Biological Technology

Development Limited, who will also supply Oramed Ltd.

with specified quantities of recombinant human insulin to be used for clinical

purchase, pursuant to separate agreements with third parties, the raw materials required for the manufacturing of our oral capsule.

We generally depend upon a limited number of suppliers for the raw materials.

Although alternative sources of supply for these

materials are generally available, we could incur significant costs and disruptions if we need to change suppliers.

The termination

of our relationships with our suppliers or the failure of these suppliers to meet our requirements for raw materials on a timely

and cost-effective basis could have a material adverse effect on our business, prospects, financial condition and results of operations.

Diabetes is a disease

5 unchanged sentences

According to the International

Diabetes Federation, or IDF, an estimated 425 million adults worldwide suffered from diabetes in 2017 and the IDF projects this

number will increase to 629 million by 2045.

Also, according to the IDF, in 2017, an estimated 4 million people died from diabetes.

According to the American Diabetes Association, or ADA, in the United States there were approximately 30.3 million people with

diabetes, or 9.4% of the United States population in 2015.

Diabetes is a leading cause of blindness, kidney failure, heart attack,

stroke and amputation.

Intellectual property :

a portfolio of patents and patent applications covering our technologies, and we are aggressively protecting these technology developments

on a worldwide basis.

We are led by an experienced

management team knowledgeable in the treatment of diabetes.

Our Chief Scientific Officer, Miriam Kidron, PhD, is a recognized pharmacologist

and a biochemist and the innovator primarily responsible for our oral insulin technology development and know-how.

Scientific Advisory Board :

management team has access to our internationally recognized Scientific Advisory Board whose members are thought-leaders in their

respective areas.

Diabetes Federation, or IDF, an estimated 463 million adults (20-79 years) worldwide suffered from diabetes in 2019 and the IDF

projects this number will increase to 700 million by 2045.

Also, according to the IDF, in 2019, an estimated 4.2 million people

died from diabetes.

According to the American Diabetes Association, or ADA, in the United States there were approximately 34.2

million people with diabetes, or 10.5% of the United States population in 2018.

Diabetes is a leading cause of blindness, kidney

failure, heart attack, stroke and amputation.

The latest report of the ADA that analyzed the economic costs of diabetes in the

U.S in 2017 indicates that the total cost of diagnosed diabetes in the United States in 2017 was $327 billion.

own a portfolio of patents and patent applications covering our technologies, and we are aggressively protecting these technology

developments on a worldwide basis.

We are led by an experienced management team knowledgeable in the treatment of diabetes.

Our Chief Scientific Officer, Miriam

Kidron, PhD, is a recognized pharmacologist and a biochemist and the innovator primarily responsible for our oral insulin technology

development and know-how.

Advisory Board :

Our management team has access to our internationally recognized Scientific Advisory Board whose members

are thought-leaders in their respective areas.

The Scientific Advisory Board is comprised of Dr.

Roy Eldor, Professor Ele Ferrannini, Dr.

Henry, Professor

Avram Hershko, Dr.

Harold Jacob and Dr.

Short Term Business Strategy

We plan to conduct further research and development

on the technology covered by the patent application “Methods and Composition for Oral Administration of Proteins,”

which we acquired from Hadasit Medical Research Services and Development Ltd.

in 2006, and which is granted in various foreign

jurisdictions, as well as the other patents we have filed in various foreign jurisdictions since then, as discussed below under

“—Patents and Licenses”

and below under “Item 1A.

Risk Factors”

Through our research and development efforts,

we have successfully developed an oral dosage form that is intended to withstand the harsh environment of the stomach and intestines

and effectively deliver active insulin or other proteins, such as exenatide, for the treatment of diabetes.

The excipients that

are added to the proteins in the formulation process are not intended to modify the proteins chemically or biologically, and the

dosage form is designed to be safe to ingest.

We plan to continue to conduct clinical trials to show the effectiveness of our technology.

As our oral insulin (ORMD-0801) Phase IIb three-month

dose-ranging clinical trial successfully met its primary endpoints, we anticipate initiating two six-month Phase III clinical trials

on both type 1 and type 2 diabetic patients, following which we expect to file a BLA with potential FDA approval by the end of

calendar year 2024.

In September 2018, the FDA cleared our IND application

for human trials of our oral GLP-1 analog capsule ORMD-0901 and we initiated a Phase I PK

trial which will evaluate the safety and the pharmacokinetics of ORMD-0901 compared to placebo.

We expect to get the results of

this study in the first calendar quarter of 2020.

Clinical trials are planned in order to substantiate

our results as well as for purposes of making future filings for drug approval.

We also plan to conduct further research and development

by deploying our proprietary drug delivery technology for the delivery of other polypeptides in addition to insulin, and to develop

other innovative pharmaceutical products.

The table below gives an overview of our primary

product pipeline:

Another component of our business strategy is

to partner with other companies or medical institutions in order to further develop our technology and commence pre-commercialization

On November 30, 2015, we, our Israeli subsidiary and HTIT entered into a Technology License Agreement, which was further

amended, according to which we granted HTIT an exclusive commercialization license in the territory of the People’s Republic

of China, Macau and Hong Kong, or the Territory, related to our oral insulin capsule, ORMD-0801.

Pursuant to this license agreement,

HTIT will conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to our subsidiary’s

technology related to the ORMD-0801 capsule, and will pay, upon the meeting of certain conditions, certain royalties and an aggregate

of approximately $37.5 million (see “Out-Licensed Technology”

We plan to seek additional partnerships or forms

of cooperation with other companies or medical institutions.

While our strategy is to partner with an appropriate party, no assurance

can be given that we will in fact be able to reach an agreeable partnership with any third party.

Under certain circumstances,

we may determine to develop one or more of our oral dosage forms on our own, either world-wide or in select territories.

Long Term Business Strategy

We plan to ultimately seek a strategic commercial

partner, or partners, with extensive experience in the development, commercialization, and marketing of insulin applications and/or

other orally digestible drugs.

We anticipate such partner or partners would be responsible for, or substantially support, late

stage clinical trials (Phase III) to increase the likelihood of obtaining regulatory approvals and registrations in the appropriate

markets in a timely manner.

We further anticipate that such partner, or partners, would also be responsible for sales, marketing

and support of our products in these markets.

Such planned strategic partnership, or partnerships, may provide a marketing and

sales infrastructure for our products as well as financial and operational support for global clinical trials, post marketing studies,

label expansions and other regulatory requirements concerning future clinical development in the United States and elsewhere.

future strategic partner, or partners, may also provide capital and expertise that would enable the partnership to develop new

oral dosage forms for other polypeptides.

While our strategy is to partner with an appropriate party, no assurance can be given

that we will in fact be able to reach an agreeable partnership with any third party.

Under certain circumstances, we may determine

to develop one or more of our oral dosage forms on our own, either world-wide or in select territories.

Other Planned Strategic Activities

In addition to developing our own oral dosage

form drug portfolio, we are, on an on-going basis, considering in-licensing and other means of obtaining additional technologies

to complement and/or expand our current product portfolio.

Our goal is to create a well-balanced product portfolio that will enhance

and complement our existing drug portfolio.

Product Development

Combination Therapy

In June 2012, we presented an abstract, which

reported the impact of ORMD-0801 delivered in combination with ORMD-0901.

The work assessed the safety and effectiveness of a combination

of oral insulin and oral exenatide treatments delivered to pigs prior to food intake.

The drug combination resulted in significantly

improved blood glucose regulation when compared to administration of each drug separately.

In the near term, we are focusing our efforts

on the development of our flagship products, oral insulin and oral exenatide.

Once these two products have progressed further in

clinical trials, we intend to conduct additional studies with the oral combination therapy.

Other Products

During the first quarter of calendar year 2017,

we began developing a new drug candidate, a weight loss treatment in the form of an oral leptin capsule.

We anticipate initiating

a proof of concept single dose study for our oral leptin drug candidate to evaluate its pharmacokinetic and pharmacodynamics (glucagon

reduction) in 10 type 1 adult diabetic patients in the fourth quarter of calendar year 2019.

We anticipate receiving the final

report of this study in the first quarter of calendar year 2020.

Raw Materials

Our oral insulin capsule is currently manufactured

by Swiss Caps AG, a member of Aenova Group GmbH .

One of our oral capsule ingredients is being

developed and produced by an Indian company.

In July 2010, Oramed Ltd.

entered into the Manufacturing

and Supply Agreement, or MSA, with Sanofi-Aventis Deutschland GMBH, or Sanofi-Aventis.

According to the MSA, Sanofi-Aventis will

supply Oramed Ltd.

with specified quantities of recombinant human insulin to be used for clinical trials.

We purchase, pursuant to separate agreements

with third parties, the raw materials required for the manufacturing of our oral capsule.

We generally depend upon a limited number

of suppliers for the raw materials.

Although alternative sources of supply for these materials are generally available, we could

incur significant costs and disruptions if we need to change suppliers.

The termination of our relationships with our suppliers

or the failure of these suppliers to meet our requirements for raw materials on a timely and cost-effective basis could have a

material adverse effect on our business, prospects, financial condition and results of operations.

Patents and Licenses

We maintain a proactive intellectual property

strategy, which includes patent filings in multiple jurisdictions, including the United States and other commercially significant

We hold 21 patent applications currently pending, with respect to various compositions, methods of production and oral

administration of proteins and exenatide.

Expiration dates for pending patents, if granted, will fall between 2026 and 2034.

We hold 77 patents, 3 of which were issued during

the fiscal year ended August 31, 2019, or fiscal 2019, including patents issued by the United States, Swiss, German, French, U.K.,

Italian, Netherlands, Swedish, Spanish, Australian, Israeli, Japanese, New Zealand, South African, Russian, Canadian, Hong Kong,

Chinese, European and Indian patent offices that cover a part of our technology, which allows for the oral delivery of proteins;

patents issued by the Australian, Canadian, European, Austrian, Belgian, French, German, Irish, Italian, Luxembourg, Monaco, Netherlands,

Norwegian, Spanish, Swedish, Swiss, U.K., Israeli, New Zealand, South African, Russian and Japanese patent offices that cover part

of our technology for the oral delivery of exenatide;

and patents issued by the European, Austrian, Belgian, Denmark, French, German,

Irish, Italian, Luxembourg, Monaco, Netherlands, Norway, Spanish, Swedish, Swiss, U.K.

and Japanese patent offices for treating

Consistent with our strategy to seek protection

in key markets worldwide, we have been and will continue to pursue the patent applications and corresponding foreign counterparts

of such applications.

We believe that our success will depend on our ability to obtain patent protection for our intellectual property.

Our patent strategy is as follows:

● Aggressively protect all current and future technological developments to assure strong and broad protection by filing patents

and/or continuations in part as appropriate,

● Protect technological developments at various levels, in a complementary manner, including the base technology, as well as

specific applications of the technology, and

● Establish comprehensive coverage in the United States and in all relevant foreign markets in anticipation of future commercialization

opportunities.

We also rely on trade secrets and unpatentable

know-how that we seek to protect, in part, by confidentiality agreements.

Our policy is to require our employees, consultants,

contractors, manufacturers, outside scientific collaborators and sponsored researchers, our board of directors, or our Board, technical

review board and other advisors, to execute confidentiality agreements upon the commencement of employment or consulting relationships

These agreements provide that all confidential information developed or made known to the individual during the course

of the individual’s relationship with us is to be kept confidential and not disclosed to third parties except in specific

limited circumstances.

We also require signed confidentiality or material transfer agreements from any company that is to receive

our confidential information.

In the case of employees, consultants and contractors, the agreements provide that all inventions

conceived by the individual while rendering services to us shall be assigned to us as the exclusive property of our Company.

can be no assurance, however, that all persons who we desire to sign such agreements will sign, or if they do, that these agreements

will not be breached, that we would have adequate remedies for any breach, or that our trade secrets or unpatentable know-how will

not otherwise become known or be independently developed by competitors.

Out-Licensed Technology

In June 2010, Oramed Ltd.

entered into a joint

venture agreement with D.N.A Biomedical Solutions Ltd., or D.N.A, for the establishment of Entera Bio LTD, or Entera.

Under the terms of a license agreement that

was entered into between Oramed Ltd.

and Entera in August 2010, we out-licensed technology to Entera, on an exclusive basis, for

the development of oral delivery drugs for certain indications to be agreed upon between the parties.

The out-licensed technology

differs from our main delivery technology that is used for oral insulin and GLP-1 analog and is subject to different patent applications.

Entera’s initial development effort is for an oral formulation for the treatment of osteoporosis.

In March 2011, we entered

into a patent transfer agreement, or the Patent Transfer Agreement, to replace the original license agreement pursuant to which

assigned to Entera all of its right, title and interest in and to the patent application that it had licensed to Entera

in August 2010.

Roy Eldor, Professor Ele Ferrannini,

Professor Avram Hershko, Dr.

Harold Jacob, Dr.

Julio Rosenstock and Dr.

plan to ultimately seek a strategic commercial partner, or partners, with extensive experience in the development, commercialization,

and marketing of insulin applications and/or other orally digestible drugs.

We anticipate such partner or partners would be responsible

for, or substantially support, late stage clinical trials (Phase III) to increase the likelihood of obtaining regulatory approvals

and registrations in the appropriate markets in a timely manner.

We further anticipate that such partner, or partners, would also

be responsible for sales, marketing and support of our products in these markets.

Such planned strategic partnership, or partnerships,

may provide a marketing and sales infrastructure for our products as well as financial and operational support for global clinical

trials, post marketing studies, label expansions and other regulatory requirements concerning future clinical development.

2015 we successfully executed this strategy when we, Oramed Ltd.

and HTIT entered into a Technology License Agreement pursuant

to which we granted HTIT an exclusive commercialization license in the territory of the People’s Republic of China, Macau

and Hong Kong, or the Territory, related to our oral insulin capsule, ORMD-0801.

Any future strategic partner, or partners, may

also provide capital and expertise that would enable the partnership to develop new oral dosage forms for other polypeptides.

While our strategy is to partner with an appropriate party, no assurance can be given that we will in fact be able to reach an

agreeable partnership with any third party.

Under certain circumstances, we may determine to develop one or more of our oral dosage

forms on our own, either world-wide or in select territories.

addition to developing our own oral dosage form drug portfolio, we are, on an on-going basis, considering in-licensing and other

means of obtaining additional technologies to complement and/or expand our current product portfolio.

Our goal is to create a

well-balanced product portfolio that will enhance and complement our existing drug portfolio.

Material Impact of COVID-19

The COVID-19 pandemic

has negatively impacted the global economy, disrupted consumer spending and global supply chains and created significant volatility

and disruption of financial markets.

Although to date the COVID-19 pandemic has not had a material adverse effect on us, the COVID-19

pandemic may have a material adverse effect on our business and financial performance in the future.

The extent of the impact of

the COVID-19 pandemic, including our ability to execute our business strategies as planned, will depend on future developments,

including the duration and severity of the pandemic, which are highly uncertain and cannot be predicted.

as of the date of this Annual Report on Form 10-K, we do not expect any material impact on our long-term activity, the extent

to which COVID-19 impacts our business will depend on future developments, which are highly uncertain and cannot be predicted,

including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its

impact, among others.

maintain a proactive intellectual property strategy, which includes patent filings in multiple jurisdictions, including the United

States and other commercially significant markets.

We hold 26 patent applications currently pending, with respect to various compositions,

methods of production and oral administration of proteins and exenatide.

Expiration dates for pending patents, if granted, will

fall between 2026 and 2039.

We hold 79 patents,

2 of which were issued during the fiscal year ended August 31, 2020, or fiscal 2020, including patents issued by the United States,

Swiss, German, French, U.K., Italian, Netherlands, Swedish, Spanish, Australian, Israeli, Japanese, New Zealand, South African,

Russian, Canadian, Hong Kong, Chinese, European and Indian patent offices that cover a part of our technology, which allows for

the oral delivery of proteins;

patents issued by the Australian, Canadian, European, Austrian, Belgian, French, German, Irish,

Italian, Luxembourg, Monaco, Netherlands, Norwegian, Spanish, Swedish, Swiss, U.K., Israeli, New Zealand, South African, Russian

and Japanese patent offices that cover part of our technology for the oral delivery of exenatide;

and patents issued by the European,

Austrian, Belgian, Denmark, French, German, Irish, Italian, Luxembourg, Monaco, Netherlands, Norway, Spanish, Swedish, Swiss, U.K.

and Japanese patent offices for treating diabetes.

with our strategy to seek protection in key markets worldwide, we have been and will continue to pursue the patent applications

and corresponding foreign counterparts of such applications.

We believe that our success will depend on our ability to obtain

patent protection for our intellectual property.

patent strategy is as follows:

● Aggressively

protect all current and future technological developments to assure strong and broad protection by filing patents and/or continuations

in part as appropriate,

technological developments at various levels, in a complementary manner, including the base technology, as well as specific applications

of the technology, and

comprehensive coverage in the United States and in all relevant foreign markets in anticipation of future commercialization opportunities.

also rely on trade secrets and unpatentable know-how that we seek to protect, in part, by confidentiality agreements.

is to require our employees, consultants, contractors, manufacturers, outside scientific collaborators and sponsored researchers,

our board of directors, or our Board, technical review board and other advisors, to execute confidentiality agreements upon the

commencement of employment or consulting relationships with us.

These agreements provide that all confidential information developed

or made known to the individual during the course of the individual’s relationship with us is to be kept confidential and

not disclosed to third parties except in specific limited circumstances.

We also require signed confidentiality or material transfer

agreements from any company that is to receive our confidential information.

In the case of employees, consultants and contractors,

the agreements provide that all inventions conceived by the individual while rendering services to us shall be assigned to us

as the exclusive property of our Company.

There can be no assurance, however, that all persons who we desire to sign such agreements

will sign, or if they do, that these agreements will not be breached, that we would have adequate remedies for any breach, or

that our trade secrets or unpatentable know-how will not otherwise become known or be independently developed by competitors.

June 2010, Oramed Ltd.

entered into a joint venture agreement with D.N.A Biomedical Solutions Ltd., or D.N.A, for the establishment

of Entera Bio Ltd., or Entera.

Under the terms of

a license agreement, as amended, that was entered into between Oramed Ltd.

and Entera in August 2010, we out-licensed technology

to Entera, on an exclusive basis, for the development of oral delivery drugs for certain indications to be agreed upon between

The out-licensed technology differs from our main delivery technology that is used for oral insulin and GLP-1 analog

and is subject to different patent applications.

Entera’s initial development effort is for an oral formulation for the treatment

of osteoporosis.

In March 2011, we entered into a patent transfer agreement, or the Patent Transfer Agreement, to replace the original

license agreement pursuant to which Oramed Ltd.

assigned to Entera all of its right, title and interest in and to the patent application

that it had licensed to Entera in August 2010.

Under this agreement, Oramed Ltd.

is entitled to receive from Entera royalties of 3% of Entera’s net revenues

(as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza.

In March 2011, we also consummated a transaction

with D.N.A, whereby we sold to D.N.A 47% of Entera’s outstanding share capital on an undiluted basis, retaining a 3% interest

as of March 2011.

In consideration for the shares sold to D.N.A, we received, among other payments, ordinary shares of D.N.A.

D.N.A ordinary shares are traded on the Tel Aviv Stock Exchange and its quoted price is subject to market fluctuations, and may,

at times, have a price below the value on the date we acquired such shares.

In addition, the ordinary shares of D.N.A have historically

experienced low trading volume;

as a result, there is no guarantee that we will be able to resell the ordinary shares of D.N.A

at the prevailing market prices.

During the years ended August 31, 2019, 2018 and 2017, we did not sell any of the D.N.A ordinary

As of August 31, 2019, we held approximately 6.9% of D.N.A’s outstanding ordinary shares.

As of August 31, 2019, Entera had not yet realized

any revenues.

In July 2018, Entera completed an initial public offering and became listed on The Nasdaq Capital Market, or Nasdaq.

In August 2018, Entera announced that it completed the treatment of patients in the first part of the PK/pharmacodynamic study

in hypoparathyroidism patients with its oral parathyroid hormone drug, EB612.

On December 11, 2018, Entera announced that it had

entered into a research collaboration and license agreement, or the Amgen License, with Amgen Inc.

related to research of inflammatory

disease and other serious illnesses.

As reported by Entera, under the terms of the Amgen License, Entera will receive a modest

initial technology access fee from Amgen and will be responsible for preclinical development at Amgen’s expense.

be eligible to receive up to $270,000,000 in aggregate payments, as well as tiered royalties up to mid-single digits, upon achievement

of various clinical and commercial milestones if Amgen decides to move all of these programs forward.

Amgen is responsible for

clinical development, manufacturing and commercialization of any of the resulting programs.

To the extent the Amgen License results

in net revenues as defined in the Patent Transfer Agreement, our Subsidiary will be entitled to the aforementioned royalties.

On November 30, 2015, we, our Israeli subsidiary

and HTIT entered into a Technology License Agreement, and on December 21, 2015, these parties entered into an Amended and Restated

Technology License Agreement that was further amended by the parties on June 3, 2016 and July 24, 2016, or the License Agreement.

According to the License Agreement, we granted HTIT an exclusive commercialization license in the Territory, related to our oral

insulin capsule, ORMD-0801, or the Product.

Pursuant to the License Agreement, HTIT will conduct, at its own expense, certain pre-commercialization

and regulatory activities with respect to our subsidiary’s technology and ORMD-0801 capsule, and will pay (i) royalties of

10% on net sales of the related commercialized products to be sold by HTIT in the Territory, or Royalties, and (ii) an aggregate

of $37.5 million, of which $3 million was payable immediately, $8 million will be paid subject to our entry into certain agreements

with certain third parties, and $26.5 million will be payable upon achievement of certain milestones and conditions.

that we will not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%.

Following the final expiration

of our patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances,

The royalty payment obligation shall apply during the period of time beginning upon the first commercial sale of the Product

in the Territory, and ending upon the later of (i) the expiration of the last-to-expire licensed patents in the Territory;

(ii) 15 years after the first commercial sale of the Product in the Territory, or the Royalty Term.

The License Agreement shall

remain in effect until the expiration of the Royalty Term.

The License Agreement contains customary termination provisions.

August 31, 2019, we received aggregate milestone payments of $20.5 million.

We also entered into a separate securities

purchase agreement with HTIT, or the SPA, pursuant to which HTIT invested $12 million in us in December 2015 (see –

“Liquidity

and capital resources”

In connection with the License Agreement and the SPA, we received a non-refundable payment

of $500,000 as a no-shop fee.

Government Regulation

The Drug Development Process

Regulatory requirements for the approval of

new drugs vary from one country to another.

In order to obtain approval to market our drug portfolio, we need to go through a different

regulatory process in each country in which we apply for such approval.

In some cases, information gathered during the approval

process in one country can be used as supporting information for the approval process in another country.

As a strategic decision,

we decided to first explore the FDA regulatory pathway.

The following is a summary of the FDA’s requirements.

The FDA requires that pharmaceutical and certain

other therapeutic products undergo significant clinical experimentation and clinical testing prior to their marketing or introduction

to the general public.

Clinical testing, known as clinical trials or clinical studies, is either conducted internally by life science,

pharmaceutical or biotechnology companies or is conducted on behalf of these companies by CROs.

The process of conducting clinical studies is

highly regulated by the FDA, as well as by other governmental and professional bodies.

Below we describe the principal framework

in which clinical studies are conducted, as well as describe a number of the parties involved in these studies.

Before commencing human clinical

studies, the sponsor of a new drug or therapeutic product must submit an IND application to the FDA.

The application contains,

among other documents, what is known in the industry as a protocol.

A protocol is the blueprint for each drug study.

sets forth, among other things, the following:

● Who must be recruited as qualified participants,

● How often to administer the drug or product,

● What tests to perform on the participants, and

● What dosage of the drug or amount of the product to give to the participants.

Institutional Review Board.

An institutional

review board is an independent committee of professionals and lay persons which reviews clinical research studies involving human

beings and is required to adhere to guidelines issued by the FDA.

The institutional review board does not report to the FDA, but

its records are audited by the FDA.

Its members are not appointed by the FDA.

All clinical studies must be approved by an institutional

is entitled to receive from Entera royalties of

3% of Entera’s net revenues and a license back of that patent application for use in respect of diabetes and influenza.

March 2011, we also consummated a transaction with D.N.A, whereby we sold to D.N.A 47% of Entera’s outstanding share capital

on an undiluted basis, retaining a 3% interest as of March 2011.

In consideration for the shares sold to D.N.A, we received, among

other payments, ordinary shares of D.N.A.

The D.N.A ordinary shares are traded on the Tel Aviv Stock Exchange and its quoted price

is subject to market fluctuations, and may, at times, have a price below the value on the date we acquired such shares.

the ordinary shares of D.N.A have historically experienced low trading volume;

as a result, there is no guarantee that we will

be able to resell the ordinary shares of D.N.A at the prevailing market prices.

During the years ended August 31, 2020, 2019 and

2018, we did not sell any of the D.N.A ordinary shares.

As of August 31, 2020, we held approximately 5.6% of D.N.A’s outstanding

ordinary shares.

As of August 31, 2020,

Entera had not yet realized any revenues.

On December 11, 2018, Entera announced that it had entered into a research collaboration

and license agreement, or the Amgen License, with Amgen Inc.

related to research of inflammatory disease and other serious illnesses.

As reported by Entera, under the terms of the Amgen License, Entera will receive a modest initial technology access fee from Amgen

and will be responsible for preclinical development at Amgen’s expense.

Entera will be eligible to receive up to $270,000,000

in aggregate payments, as well as tiered royalties up to mid-single digits, upon achievement of various clinical and commercial

milestones if Amgen decides to move all of these programs forward.

To the extent the Amgen License results in net revenues as defined

in the Patent Transfer Agreement, Oramed Ltd.

will be entitled to the aforementioned royalties.

November 30, 2015, we, Oramed Ltd.

and HTIT entered into a Technology License Agreement, or TLA, and on December 21, 2015, these

parties entered into an Amended and Restated Technology License Agreement that was further amended by the parties on June 3, 2016

and July 24, 2016, or the License Agreement.

According to the License Agreement, we granted HTIT an exclusive commercialization

license in the Territory, related to our oral insulin capsule, ORMD-0801, or the Product.

Pursuant to the License Agreement, HTIT

will conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to our subsidiary’s

technology and ORMD-0801 capsule, and will pay (i) royalties of 10% on net sales of the related commercialized products to be

sold by HTIT in the Territory, or Royalties, and (ii) an aggregate of $37.5 million, of which $3 million was payable immediately,

$8 million will be paid subject to our entry into certain agreements with certain third parties, and $26.5 million will be payable

upon achievement of certain milestones and conditions.

In the event that we will not meet certain conditions, the Royalties rate

may be reduced to a minimum of 8%.

Following the final expiration of our patents covering the technology in the Territory in 2033,

the Royalties rate may be reduced, under certain circumstances, to 5%.

The royalty payment obligation shall apply during the period

of time beginning upon the first commercial sale of the Product in the Territory, and ending upon the later of (i) the expiration

of the last-to-expire licensed patents in the Territory;

and (ii) 15 years after the first commercial sale of the Product in the

Territory, or the Royalty Term.

The License Agreement shall remain in effect until the expiration of the Royalty Term.

Agreement contains customary termination provisions.

Through August 31, 2020, we received aggregate milestone payments of $20.5

On August 21, 2020, we received a

letter from HTIT, disputing certain pending payment obligations of HTIT under the TLA.

The payment obligation being disputed is

$4 million, out of which only an amount of $2 million has been received and has been included in Deferred revenue in each of the

consolidated balance sheets as of the fiscal years ended August 31, 2020, and 2019.

In addition, the dispute includes a payment

obligation of $2 million for certain milestones that we assert it met under the TLA subsequent to the fiscal year ended August

We wholly dispute the claims made by HTIT and has been engaged in discussions and exchanges with HTIT in an attempt to

clarify and resolve disagreements between the parties regarding milestone payments and work plan implementation.

also entered into a separate securities purchase agreement with HTIT, or the SPA, pursuant to which HTIT invested $12 million

in us in December 2015.

In connection with the License Agreement and the SPA, we received a non-refundable payment of $500,000

as a no-shop fee.

Drug Development Process

requirements for the approval of new drugs vary from one country to another.

In order to obtain approval to market our drug portfolio,

we need to go through a different regulatory process in each country in which we apply for such approval.

In some cases, information

gathered during the approval process in one country can be used as supporting information for the approval process in another

As a strategic decision, we decided to first explore the FDA regulatory pathway.

The following is a summary of the FDA’s

requirements.

FDA requires that pharmaceutical and certain other therapeutic products undergo significant clinical experimentation and clinical

testing prior to their marketing or introduction to the general public.

Clinical testing, known as clinical trials or clinical

studies, is either conducted internally by life science, pharmaceutical or biotechnology companies or is conducted on behalf of

these companies by CROs.

process of conducting clinical studies is highly regulated by the FDA, as well as by other governmental and professional bodies.

Below we describe the principal framework in which clinical studies are conducted, as well as describe a number of the parties

involved in these studies.

Before commencing human clinical studies, the sponsor of a new drug or therapeutic product must submit an IND application to the

The application contains, among other documents, what is known in the industry as a protocol.

A protocol is the blueprint

for each drug study.

The protocol sets forth, among other things, the following:

must be recruited as qualified participants,

often to administer the drug or product,

tests to perform on the participants, and

dosage of the drug or amount of the product to give to the participants.

Institutional

Review Board.

The institutional review board’s role is to protect the rights of the participants in the clinical studies.

It approves the protocols to be used, the advertisements which the company or CRO conducting the study proposes to use to recruit

participants, and the form of consent which the participants will be required to sign prior to their participation in the clinical

Clinical Trials.

Human clinical studies or testing

of a potential product are generally done in three stages known as Phase I through Phase III testing.

The names of the phases are

derived from the regulations of the FDA.

Generally, there are multiple studies conducted in each phase.

Phase I studies involve testing a drug

or product on a limited number of healthy or patient participants, typically 24 to 100 people at a time.

Phase I studies determine

a product’s basic safety and how the product is absorbed by, and eliminated from, the body.

This phase lasts an average of

six months to a year.

Phase II trials involve testing of

no more than 300 participants at a time who may suffer from the targeted disease or condition.

Phase II testing typically lasts

an average of one to two years.

In Phase II, the drug is tested to determine its safety and effectiveness for treating a specific

illness or condition.

An institutional review board is an independent committee of professionals and lay persons which reviews clinical

research studies involving human beings and is required to adhere to guidelines issued by the FDA.

The institutional review board

does not report to the FDA, but its records are audited by the FDA.

Its members are not appointed by the FDA.

All clinical studies

must be approved by an institutional review board.

The institutional review board’s role is to protect the rights of the

participants in the clinical studies.

It approves the protocols to be used, the advertisements which the company or CRO conducting

the study proposes to use to recruit participants, and the form of consent which the participants will be required to sign prior

to their participation in the clinical studies.

Human clinical studies or testing of a potential product are generally done in three stages known as Phase I through Phase

The names of the phases are derived from the regulations of the FDA.

Generally, there are multiple studies conducted

in each phase.

Phase I studies involve testing a drug or product on a limited number of healthy or patient participants, typically 24 to 100

people at a time.

Phase I studies determine a product’s basic safety and how the product is absorbed by, and eliminated

from, the body.

This phase lasts an average of six months to a year.

Phase II trials involve testing of no more than 300 participants at a time who may suffer from the targeted disease or condition.

Phase II testing typically lasts an average of one to two years.

In Phase II, the drug is tested to determine its safety and effectiveness

for treating a specific illness or condition.

Phase II testing also involves determining acceptable dosage levels of the drug.

Phase II studies may be

split into Phase IIa and Phase IIb sub-studies.

Phase IIa studies may be conducted with patient volunteers and are exploratory

(non-pivotal) studies, typically designed to evaluate clinical efficacy or biological activity.

Phase IIb studies are conducted

with patients defined to evaluate definite dose range and evaluate efficacy.

If Phase II studies show that a new drug has an acceptable

range of safety risks and probable effectiveness, a company will generally continue to review the substance in Phase III studies.

Phase III studies involve testing

large numbers of participants, typically several hundred to several thousand persons.

The purpose is to verify effectiveness and

long-term safety on a large scale.

Phase II studies may be split into Phase IIa and Phase IIb sub-studies.

Phase IIa studies may be conducted with patient volunteers

and are exploratory (non-pivotal) studies, typically designed to evaluate clinical efficacy or biological activity.

studies are conducted with patients defined to evaluate definite dose range and evaluate efficacy.

If Phase II studies show that

a new drug has an acceptable range of safety risks and probable effectiveness, a company will generally continue to review the

substance in Phase III studies.

Phase III studies involve testing large numbers of participants, typically several hundred to several thousand persons.

purpose is to verify effectiveness and long-term safety on a large scale.

These studies generally last two to three years.

Phase III studies are conducted at multiple

locations or sites.

Like the other phases, Phase III requires the site to keep detailed records of data collected and procedures

Biological License Application.

of the clinical trials for a biological product are submitted to the FDA as part of a BLA.

Following the completion of Phase III

studies, assuming the sponsor of a potential product in the United States believes it has sufficient information to support the

safety and effectiveness of its product, the sponsor will generally submit a BLA to the FDA requesting that the product be approved

for marketing.

The application is a comprehensive, multi-volume filing that includes the results of all clinical studies, information

about the drug’s composition, and the sponsor’s plans for producing, packaging and labeling the product.

The FDA’s

review of an application can take a few months to many years, with the average review lasting 18 months.

Once approved, drugs and

other products may be marketed in the United States, subject to any conditions imposed by the FDA.

Approval of a BLA provides 12

years of exclusivity in the U.S.

The FDA may require that the sponsor

conduct additional clinical trials following new drug approval.

The purpose of these trials, known as Phase IV studies, is to monitor

long-term risks and benefits, study different dosage levels or evaluate safety and effectiveness.

In recent years, the FDA has

increased its reliance on these trials.

Phase IV studies usually involve thousands of participants.

Phase IV studies also may be

initiated by the company sponsoring the new drug to gain broader market value for an approved drug.

Similar to the U.S., a European sponsor of a

biological product may submit a Marketing Approval Application to the EMA for the registration of the product.

The approval process

in Europe consists of several stages, which together are summed up to 210 days from the time of submission of the application (net,

without periods in which the sponsor provides answers to questions raised by the agency) following which, a Marketing Approval

may be granted.

During the approval process, the sponsor’s manufacturing facilities will be audited in order to assess Good

Manufacturing Practice compliance.

The drug approval process is time-consuming,

involves substantial expenditures of resources, and depends upon a number of factors, including the severity of the illness in

question, the availability of alternative treatments, and the risks and benefits demonstrated in the clinical trials.

Other Regulations

Various federal, state and local laws, regulations,

and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, the environment

and the purchase, storage, movement, import, export, use, and disposal of hazardous or potentially hazardous substances, including

radioactive compounds and infectious disease agents, used in connection with our research are applicable to our activities.

include, among others, the U.S.

Atomic Energy Act, the Clean Air Act, the Clean Water Act, the Occupational Safety and Health Act,

the National Environmental Policy Act, the Toxic Substances Control Act, and Resources Conservation and Recovery Act, national

restrictions on technology transfer, import, export, and customs regulations, and other present and possible future local, state,

or federal regulation.

The compliance with these and other laws, regulations and recommendations can be time-consuming and involve

substantial costs.

In addition, the extent of governmental regulation which might result from future legislation or administrative

action cannot be accurately predicted and may have a material adverse effect on our business, financial condition, results of operations

and prospects.

Competition in General

Competition in the area of biomedical and pharmaceutical

research and development is intense and significantly depends on scientific and technological factors.

These factors include the

availability of patent and other protection for technology and products, the ability to commercialize technological developments

and the ability to obtain regulatory approval for testing, manufacturing and marketing.

Our competitors include major pharmaceutical,

medical products, chemical and specialized biotechnology companies, many of which have financial, technical and marketing resources

significantly greater than ours.

In addition, many biotechnology companies have formed collaborations with large, established companies

to support research, development and commercialization of products that may be competitive with ours.

Academic institutions, governmental

agencies and other public and private research organizations are also conducting research activities and seeking patent protection

and may commercialize products on their own or through joint ventures.

We are aware of certain other products manufactured or under

development by competitors that are used for the treatment of the diseases and health conditions that we have targeted for product

We can provide no assurance that developments by others will not render our technology obsolete or noncompetitive,

that we will be able to keep pace with new technological developments or that our technology will be able to supplant established

products and methodologies in the therapeutic areas that are targeted by us.

The foregoing factors could have a material adverse

effect on our business, prospects, financial condition and results of operations.

These companies, as well as academic institutions,

governmental agencies and private research organizations, also compete with us in recruiting and retaining highly qualified scientific

personnel and consultants.

Competition within our sector is increasing,

so we will encounter competition from existing firms that offer competitive solutions in diabetes treatment solutions.

These competitive

companies could develop products that are superior to, or have greater market acceptance, than the products being developed by

We will have to compete against other biotechnology and pharmaceutical companies with greater market recognition and greater

financial, marketing and other resources.

Our competition will be determined in part by

the potential indications for which our technology is developed and ultimately approved by regulatory authorities.

the first product to reach the market in a therapeutic or preventive area is often at a significant competitive advantage relative

to later entrants to the market.

Accordingly, the relative speed with which we, or our potential corporate partners, can develop

products, complete the clinical trials and approval processes and supply commercial quantities of the products to the market are

expected to be important competitive factors.

Our competitive position will also depend on our ability to attract and retain qualified

scientific and other personnel, develop effective proprietary products, develop and implement production and marketing plans, obtain

and maintain patent protection and secure adequate capital resources.

We expect our technology, if approved for sale, to compete

primarily on the basis of product efficacy, safety, patient convenience, reliability, value and patent position.

Competition for Our Oral Insulin Capsule

We anticipate the oral insulin capsule to be

a competitive diabetes drug because of its anticipated efficacy and safety profile.

The following are some of the treatment options

for type 1 and type 2 diabetic patients:

● Insulin injections,

● Insulin pumps, or

● A combination of diet, exercise and oral medication which improve the body’s response to insulin or cause the body to

produce more insulin.

Scientific Advisory Board

We maintain a Scientific Advisory Board consisting

of internationally recognized scientists who advise us on scientific and technical aspects of our business.

The Scientific Advisory

Board meets periodically to review specific projects and to assess the value of new technologies and developments to us.

individual members of the Scientific Advisory Board meet with us periodically to provide advice in their particular areas of expertise.

The Scientific Advisory Board consists of the following members, information with respect to whom is set forth below:

Professor Ele Ferrannini, Dr.

Henry, Professor Avram Hershko, Dr.

Harold Jacob and Dr.

Roy Eldor , MD, PhD,

joined the Oramed Scientific Advisory Board in July 2016.

He is an endocrinologist, internist and researcher with over twenty years

of clinical and scientific experience.

He is currently Director of the Diabetes Unit at the Institute of Endocrinology, Metabolism

& Hypertension, Tel-Aviv Sourasky Medical Center.

III studies are conducted at multiple locations or sites.

Like the other phases, Phase III requires the site to keep detailed

records of data collected and procedures performed.

License Application.

The results of the clinical trials for a biological product are submitted to the FDA as part of a BLA.

the completion of Phase III studies, assuming the sponsor of a potential product in the United States believes it has sufficient

information to support the safety and effectiveness of its product, the sponsor will generally submit a BLA to the FDA requesting

that the product be approved for marketing.

The application is a comprehensive, multi-volume filing that includes the results

of all clinical studies, information about the drug’s composition, and the sponsor’s plans for producing, packaging

and labeling the product.

The FDA’s review of an application can take a few months to many years, with the average review

lasting 18 months.

Once approved, drugs and other products may be marketed in the United States, subject to any conditions imposed

Approval of a BLA provides 12 years of exclusivity in the U.S.

The FDA may require that the sponsor conduct additional clinical trials following new drug approval.

The purpose of these

trials, known as Phase IV studies, is to monitor long-term risks and benefits, study different dosage levels or evaluate safety

and effectiveness.

In recent years, the FDA has increased its reliance on these trials.

Phase IV studies usually involve thousands

of participants.

Phase IV studies also may be initiated by the company sponsoring the new drug to gain broader market value for

an approved drug.

to the U.S., a European sponsor of a biological product may submit a Marketing Approval Application to the EMA for the registration

of the product.

The approval process in Europe consists of several stages, which together are summed up to 210 days from the time

of submission of the application (net, without periods in which the sponsor provides answers to questions raised by the agency)

following which, a Marketing Approval may be granted.

During the approval process, the sponsor’s manufacturing facilities

will be audited in order to assess Good Manufacturing Practice compliance.

drug approval process is time-consuming, involves substantial expenditures of resources, and depends upon a number of factors,

including the severity of the illness in question, the availability of alternative treatments, and the risks and benefits demonstrated

in the clinical trials.

federal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory practices, the

experimental use of animals, the environment and the purchase, storage, movement, import, export, use, and disposal of hazardous

or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our

research are applicable to our activities.

They include, among others, the U.S.

Atomic Energy Act, the Clean Air Act, the Clean

Water Act, the Occupational Safety and Health Act, the National Environmental Policy Act, the Toxic Substances Control Act, and

Resources Conservation and Recovery Act, national restrictions on technology transfer, import, export, and customs regulations,

and other present and possible future local, state, or federal regulation.

The compliance with these and other laws, regulations

and recommendations can be time-consuming and involve substantial costs.

In addition, the extent of governmental regulation which

might result from future legislation or administrative action cannot be accurately predicted and may have a material adverse effect

on our business, financial condition, results of operations and prospects.

in the area of biomedical and pharmaceutical research and development is intense and significantly depends on scientific and technological

These factors include the availability of patent and other protection for technology and products, the ability to commercialize

technological developments and the ability to obtain regulatory approval for testing, manufacturing and marketing.

Our competitors

include major pharmaceutical, medical products, chemical and specialized biotechnology companies, many of which have financial,

technical and marketing resources significantly greater than ours.

In addition, many biotechnology companies have formed collaborations

with large, established companies to support research, development and commercialization of products that may be competitive with

Academic institutions, governmental agencies and other public and private research organizations are also conducting research

activities and seeking patent protection and may commercialize products on their own or through joint ventures.

We are aware of

certain other products manufactured or under development by competitors that are used for the treatment of the diseases and health

conditions that we have targeted for product development.

We can provide no assurance that developments by others will not render

our technology obsolete or noncompetitive, that we will be able to keep pace with new technological developments or that our technology

will be able to supplant established products and methodologies in the therapeutic areas that are targeted by us.

The foregoing

factors could have a material adverse effect on our business, prospects, financial condition and results of operations.

companies, as well as academic institutions, governmental agencies and private research organizations, also compete with us in

recruiting and retaining highly qualified scientific personnel and consultants.

within our sector is increasing, so we will encounter competition from existing firms that offer competitive solutions in diabetes

treatment solutions.

These competitive companies could develop products that are superior to, or have greater market acceptance,

than the products being developed by us.

We will have to compete against other biotechnology and pharmaceutical companies with

greater market recognition and greater financial, marketing and other resources.

competition will be determined in part by the potential indications for which our technology is developed and ultimately approved

by regulatory authorities.

In addition, the first product to reach the market in a therapeutic or preventive area is often at

a significant competitive advantage relative to later entrants to the market.

Accordingly, the relative speed with which we, or

our potential corporate partners, can develop products, complete the clinical trials and approval processes and supply commercial

quantities of the products to the market are expected to be important competitive factors.

Our competitive position will also

depend on our ability to attract and retain qualified scientific and other personnel, develop effective proprietary products,

develop and implement production and marketing plans, obtain and maintain patent protection and secure adequate capital resources.

We expect our technology, if approved for sale, to compete primarily on the basis of product efficacy, safety, patient convenience,

reliability, value and patent position.

for Our Oral Insulin Capsule

anticipate the oral insulin capsule to be a competitive diabetes drug because of its anticipated efficacy and safety profile.

The following are some of the treatment options for type 1 and type 2 diabetic patients:

combination of diet, exercise and oral medication which improve the body’s response to insulin or cause the body to produce

more insulin.

Advisory Board

maintain a Scientific Advisory Board consisting of internationally recognized scientists who advise us on scientific and technical

aspects of our business.

The Scientific Advisory Board meets periodically to review specific projects and to assess the value

of new technologies and developments to us.

In addition, individual members of the Scientific Advisory Board meet with us periodically

to provide advice in their particular areas of expertise.

The Scientific Advisory Board consists of the following members, information

with respect to whom is set forth below:

Roy Eldor, Professor Ele Ferrannini, Professor Avram Hershko, Dr.

Harold Jacob, Dr.

Julio Rosenstock and Dr.

Roy Eldor , MD, PhD, joined the Oramed Scientific Advisory Board in July 2016.

He is an endocrinologist, internist

and researcher with over twenty years of clinical and scientific experience.

He is currently Director of the Diabetes Unit at

the Institute of Endocrinology, Metabolism & Hypertension, Tel-Aviv Sourasky Medical Center.

Prior to that, Dr.

Eldor served as Principal Scientist at Merck Research

Laboratories, Clinical Research - Diabetes & Endocrinology, Rahway, New Jersey.

He has previously served as a senior physician

in internal medicine at the Diabetes Unit in Hadassah Hebrew University Hospital, Jerusalem, Israel;

and the Diabetes Division

at the University of Texas Health Science Center in San Antonio, Texas (under the guidance of Dr.

a recognized expert, with over 35 peer reviewed papers and book chapters, and has been a guest speaker at numerous international

Professor Ele Ferrannini , MD, joined

the Oramed Scientific Advisory Board in February 2007.

He is a past President to the European Association for the Study of Diabetes,

which supports scientists, physicians and students from all over the world who are interested in diabetes and related subjects

in Europe, and performs functions similar to that of the ADA in the United States.

Professor Ferrannini has worked with various

institutions including the Department of Clinical & Experimental Medicine, University of Pisa School of Medicine, and CNR (National

Research Council) Institute of Clinical Physiology, Pisa, Italy;

and the Diabetes Division, Department of Medicine, University

of Texas Health Science Center at San Antonio, Texas.

He has also had extensive training in internal medicine and endocrinology,

and has specialized in diabetes studies.

Professor Ferrannini has received a Certificate of the Educational Council for Foreign

Medical Graduates from the University of Bologna, and with cum laude honors completed a subspecialty in Diabetes and Metabolic

Diseases at the University of Torino.

He has published over 500 original papers and 50 book chapters and he is a “highly

cited researcher,”

as Principal Scientist at Merck Research Laboratories, Clinical Research - Diabetes & Endocrinology, Rahway, New Jersey.

has previously served as a senior physician in internal medicine at the Diabetes Unit in Hadassah Hebrew University Hospital,

Jerusalem, Israel;

and the Diabetes Division at the University of Texas Health Science Center in San Antonio, Texas (under the

guidance of Dr.

Eldor is a recognized expert, with over 35 peer reviewed papers and book chapters, and has

been a guest speaker at numerous international forums.

Ele Ferrannini , MD, joined the Oramed Scientific Advisory Board in February 2007.

He is a past President to the

European Association for the Study of Diabetes, which supports scientists, physicians and students from all over the world who

are interested in diabetes and related subjects in Europe, and performs functions similar to that of the ADA in the United States.

Professor Ferrannini has worked with various institutions including the Department of Clinical & Experimental Medicine, University

of Pisa School of Medicine, and CNR (National Research Council) Institute of Clinical Physiology, Pisa, Italy;

and the Diabetes

Division, Department of Medicine, University of Texas Health Science Center at San Antonio, Texas.

He has also had extensive training

in internal medicine and endocrinology, and has specialized in diabetes studies.

Professor Ferrannini has received a Certificate

of the Educational Council for Foreign Medical Graduates from the University of Bologna, and with cum laude honors completed a

subspecialty in Diabetes and Metabolic Diseases at the University of Torino.

He has published over 500 original papers and 50

book chapters and he is a “highly cited researcher,”

according to the Institute for Scientific Information.

Henry, MD , joined

the Oramed Scientific Advisory Board in February 2018 and is a leader in diabetes research.

As a past President of the ADA and

recipient of its Banting Medal for Scientific Achievement, among other international recognitions, his basic and clinical research

funded by the National Institutes of Health, or NIH, has resulted in more than 400 journal articles, chapters and books.

is currently Chief of the Section of Endocrinology, Metabolism & Diabetes, Veterans Affairs Healthcare System in San Diego,

California, Professor of Medicine at the University of California, San Diego and Chief of the Center for Metabolic Research in

San Diego, California.

In addition to studying the metabolic and cardiovascular effects of human skeletal muscle and adipose tissue

signaling and interactions, his current clinical research interests involve the study and development of new therapies for type

1 and type 2 diabetes and obesity.

Professor Avram Hershko, MD, PhD ,

joined the Oramed Scientific Advisory Board in July 2008.

He earned his MD degree (1965) and PhD degree (1969) from the Hebrew

University-Hadassah Medical School of Jerusalem.

Professor Hershko served as a physician in the Israel Defense Forces from 1965

After a post-doctoral fellowship with Gordon Tomkins at the University of San Francisco (1969 - 72), he joined the

faculty of the Haifa Technion becoming a professor in 1980.

He is now Distinguished Professor in the Unit of Biochemistry in the

Avram Hershko, MD, PhD , joined the Oramed Scientific Advisory Board in July 2008.

He earned his MD degree (1965) and PhD

degree (1969) from the Hebrew University-Hadassah Medical School of Jerusalem.

Professor Hershko served as a physician in the

Israel Defense Forces from 1965 to 1967.

After a post-doctoral fellowship with Gordon Tomkins at the University of San Francisco

(1969 - 72), he joined the faculty of the Haifa Technion becoming a professor in 1980.

He is now Distinguished Professor

in the Unit of Biochemistry in the B.

Rappaport Faculty of Medicine of the Technion.

Professor Hershko’s main research interests concern the mechanisms by which

cellular proteins are degraded, a formerly neglected field of study.

Professor Hershko and his colleagues showed that cellular

proteins are degraded by a highly selective proteolytic system.

This system tags proteins for destruction by linkage to a protein

called ubiquitin, which had previously been identified in many tissues, but whose function was previously unknown.

Subsequent work

by Professor Hershko and many other laboratories has shown that the ubiquitin system has a vital role in controlling a wide range

of cellular processes, such as the regulation of cell division, signal transduction and DNA repair.

Professor Hershko was awarded

the Nobel Prize in Chemistry (2004) jointly with his former PhD student Aaron Ciechanover and their colleague Irwin Rose.

honors include the Israel Prize for Biochemistry (1994), the Gairdner Award (1999), the Lasker Prize for Basic Medical Research

(2000), the Wolf Prize for Medicine (2001) and the Louisa Gross Horwitz Award (2001).

Professor Hershko is a member of the Israel

Academy of Sciences (2000) and a Foreign Associate of the U.S.

Professor Hershko’s main research interests

concern the mechanisms by which cellular proteins are degraded, a formerly neglected field of study.

Professor Hershko and his

colleagues showed that cellular proteins are degraded by a highly selective proteolytic system.

This system tags proteins for

destruction by linkage to a protein called ubiquitin, which had previously been identified in many tissues, but whose function

was previously unknown.

Subsequent work by Professor Hershko and many other laboratories has shown that the ubiquitin system has

a vital role in controlling a wide range of cellular processes, such as the regulation of cell division, signal transduction and

Professor Hershko was awarded the Nobel Prize in Chemistry (2004) jointly with his former PhD student Aaron Ciechanover

and their colleague Irwin Rose.

His many honors include the Israel Prize for Biochemistry (1994), the Gairdner Award (1999), the

Lasker Prize for Basic Medical Research (2000), the Wolf Prize for Medicine (2001) and the Louisa Gross Horwitz Award (2001).

Professor Hershko is a member of the Israel Academy of Sciences (2000) and a Foreign Associate of the U.S.

Academy of Sciences

Harold Jacob, MD , joined the

Oramed Scientific Advisory Board in November 2016.

Harold Jacob, MD , joined the Oramed Scientific Advisory Board in November 2016.

Since 1998, Dr.

Jacob has served as the president of Medical Instrument Development

Inc., a company which provides a range of support and consulting services to start-up and early stage companies as well as patenting

its own proprietary medical devices.

Jacob has served as the

president of Medical Instrument Development Inc., a company which provides a range of support and consulting services to start-up

and early stage companies as well as patenting its own proprietary medical devices.

Since 2011, Dr.

Jacob has also served as an attending physician at Hadassah University Medical

Center, where he has served as the director of the gastrointestinal endoscopy unit since September 2013.

Jacob has advised

a spectrum of companies in the past and he served as a consultant and then as the Director of Medical Affairs at Given Imaging

Ltd., from 1997 to 2003, a company that developed the first swallowable wireless pill camera for inspection of the intestine.

has licensed patents to a number of companies including Kimberly-Clark Corporation.

Jacob has also served as an

attending physician at Hadassah University Medical Center, where he has served as the director of the gastrointestinal endoscopy

unit since September 2013.

Jacob has advised a spectrum of companies in the past and he served as a consultant and then as

the Director of Medical Affairs at Given Imaging Ltd., from 1997 to 2003, a company that developed the first swallowable wireless

pill camera for inspection of the intestine.

He has licensed patents to a number of companies including Kimberly-Clark Corporation.

Since 2014, Dr.

Jacob has served as the Chief

Medical Officer and a director of NanoVibronix, Inc., a medical device company using surface acoustics to prevent catheter acquired

infection as well as other applications, where he served as Chief Executive Officer from 2004 to 2014.

He practiced clinical gastroenterology

in New York and served as Chief of Gastroenterology at St.

John’s Episcopal Hospital and South Nassau Communities Hospital

from 1986 to 1995, and was a Clinical Assistant Professor of Medicine at SUNY from 1983 to 1990.

Jacob founded and served as

Editor in Chief of Endoscopy Review and has authored numerous publications in the field of gastroenterology.

Reusch, MD , joined

the Oramed Scientific Advisory Board in February 2018.

She is a distinguished academic physician-scientist-diabetologist committed

to understanding and treating the vascular complications of diabetes.

She is currently Professor of Medicine and Associate Director,

Center for Women’s Health, at the University of Colorado at Denver and Director of the Diabetes Care Team at the Veteran’s

Administration Medical Center in Denver, Colorado.

Reusch has been awarded numerous NIH Research Project Grant (R01) and VA

Merit grants for both basic and clinical research, leading to more than 100 peer-reviewed publications on diabetes and diabetic

vascular complications.

In a continuation of her life-long service to the diabetes community, Dr.

Reusch is a previous ADA President

for Medicine and Science.

We have been successful in retaining experienced

personnel involved in our research and development program.

In addition, we believe we have successfully recruited the clinical/regulatory,

quality assurance and other personnel needed to advance through clinical studies or have engaged the services of experts in the

field for these requirements.

As of August 31, 2019, we have contracted with thirteen individuals for employment or consulting

arrangements.

Of our staff, four are senior management, five are engaged in research and development work, and the remaining four

are involved in administration work.

Additional Information

Additional information about us is contained

on our Internet website at www.oramed.com.

Information on our website is not incorporated by reference into this report.

website, under “Investors”, “SEC Filings”, we make available free of charge our Annual Reports on Form

10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant

to Section 13(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as soon as reasonably practicable after

we electronically file such material with, or furnish it to, the SEC.

Reports filed with the SEC are made available on its

website at www.sec.gov.

The following Corporate Governance documents are also posted on our website:

Code of Ethics, Whistleblowing

Policy and the Charters for each of the Audit Committee, Compensation Committee and Nominating Committee of our Board.

Jacob has served as the Chief Medical Officer and a director of NanoVibronix, Inc., a medical device company using

surface acoustics to prevent catheter acquired infection as well as other applications, where he served as Chief Executive Officer

from 2004 to 2014.

He practiced clinical gastroenterology in New York and served as Chief of Gastroenterology at St.

Episcopal Hospital and South Nassau Communities Hospital from 1986 to 1995, and was a Clinical Assistant Professor of Medicine

at SUNY from 1983 to 1990.

Jacob founded and served as Editor in Chief of Endoscopy Review and has authored numerous publications

in the field of gastroenterology.

Julio Rosenstock, MD , joined the Oramed Scientific Advisory Board in January 2020.

Rosenstock is the current Director

of the Dallas Diabetes Research Center at Medical City Dallas and a Clinical Professor of Medicine at the University of Texas

Southwestern Medical Center, Dallas.

He received his medical degree from the University of Costa Rica School of Medicine and completed

Fellowships in Endocrinology and Diabetes at the Royal Postgraduate Medical School, Hammersmith Hospital, London, UK, and at the

University of Texas Southwestern Medical Center.

His clinical research efforts focus on exploring novel agents and therapeutic

strategies to improve glycemic control.

Over the last 30 years, he has participated in hundreds of clinical trials and has had

an active role in the development of new oral agents and insulin preparations acting often as a lead clinical investigator and

scientific advisor.

He has authored or co-authored 296 peer-reviewed manuscripts and numerous abstracts.

Rosenstock is a member

of the National Board of Directors of the ADA and is currently an Associate Editor of Diabetes Care.

Jay Skyler, MD, MCAP , joined the Oramed Scientific Advisory Board in January 2020.

Skyler is Professor of Medicine,

Pediatrics, & Psychology in the Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, University of

Miami Leonard M.

Miller School of Medicine.

He previously held the position of Director of the Division of Endocrinology, Diabetes

& Metabolism.

In addition, Dr.

Skyler is Deputy Director of Clinical Research and Academic Programs at the Diabetes Research

Institute, and an Adjunct Professor of Pediatrics at the Barbara Davis Center for Childhood Diabetes, University of Colorado at

Skyler’s research focuses on the clinical aspects of diabetes, specifically the conduct of randomized controlled

clinical trials.

From 1993 until 2015, he was Chairman of the NIH (NIDDK)-sponsored Diabetes Prevention Trial - Type 1 (DPT-1)

and its successor Type 1 Diabetes TrialNet, a nationwide (and global) network conducting clinical trials to prevent type 1 diabetes.

have been successful in retaining experienced personnel involved in our research and development program.

In addition, we believe

we have successfully recruited the clinical/regulatory, quality assurance and other personnel needed to advance through clinical

studies or have engaged the services of experts in the field for these requirements.

As of August 31, 2020, we have contracted

with twelve individuals for employment or consulting arrangements.

Of our staff, four are senior management, four are engaged

in research and development work, and the remaining four are involved in administration work.

information about us is contained on our Internet website at www.oramed.com.

Information on our website is not incorporated by

reference into this report.

On our website, under “Investors”, “SEC Filings”, we make available free of

charge our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports

filed or furnished pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as soon

as reasonably practicable after we electronically file such material with, or furnish it to, the U.S.

Securities and Exchange

Commission, or the SEC.

Reports filed with the SEC are made available on its website at www.sec.gov.

The following Corporate Governance

documents are also posted on our website:

Code of Ethics, Whistleblowing Policy and the Charters for each of the Audit Committee,

Compensation Committee and Nominating Committee of our Board.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business